External Validation and Comparison of Two Nomograms Predicting the Probability of Lymph Node Involvement in Patients subjected to Robot-Assisted Radical Prostatectomy and Concomitant Lymph Node Dissection: A Single Tertiary Center Experience in the MRI-Era

Nicola Frego 1,2, Marco Paciotti 1,2, Nicolò Maria Buffi 1,2, Davide Maffei 1,2, Roberto Contieri 1,2, Pier Paolo Avolio 1,2, Vittorio Fasulo 1,2, Alessandro Uleri 1,2, Massimo Lazzeri 1,2, Rodolfo Hurle 1,2, Alberto Saita 1,2, Giorgio Ferruccio Guazzoni 1,2, Paolo Casale 1,2 and Giovanni Lughezzani 1,2*

1 Department of Biomedical Sciences, Humanitas University, Milan, Italy, 2 Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy

Introduction: To externally validate and directly compare the performance of the Briganti 2012 and Briganti 2019 nomograms as predictors of lymph node invasion (LNI) in a cohort of patients treated with robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection (ePLND).

Materials and Methods: After the exclusion of patients with incomplete biopsy, imaging, or clinical data, 752 patients who underwent RARP and ePLND between December 2014 to August 2021 at our center, were included. Among these patients, 327 (43.5%) had undergone multi-parametric MRI (mpMRI) and mpMRI-targeted biopsy. The preoperative risk of LNI was calculated for all patients using the Briganti 2012 nomogram, while the Briganti 2019 nomogram was used only in patients who had performed mpMRI with the combination of targeted and systematic biopsy. The performances of Briganti 2012 and 2019 models were evaluated using the area under the receiver-operating characteristics curve analysis, calibrations plot, and decision curve analysis.

Results: A median of 13 (IQR 9–18) nodes per patient was removed, and 78 (10.4%) patients had LNI at final pathology. The area under the curves (AUCs) for Briganti 2012 and 2019 were 0.84 and 0.82, respectively. The calibration plots showed a good correlation between the predicted probabilities and the observed proportion of LNI for both models, with a slight tendency to underestimation. The decision curve analysis...
INTRODUCTION

Lymph node invasion represents a key prognostic factor for patients affected by prostate cancer (PCa), being associated with a higher risk of biochemical and disease-recurrence as well as cancer-specific mortality (1, 2). Despite the efforts in developing new imaging techniques for nodal staging, extended pelvic lymph node dissection (ePLND) at the time of radical prostatectomy (RP) still represents the current gold standard for the detection of lymph node invasion (LNI) (3, 4). Although its undisputed prognostic and staging role, ePLND remains an invasive procedure associated with a non-negligible risk of intra- and post-operative complications, with a controversial therapeutic value (5–8). To limit the number of unnecessary lymphadenectomies, the European Association of Urology (EAU) guidelines recommend performing ePLNDs in patients with a significant risk of LNI according to currently available nomograms (3). Among them, the Briganti 2012 achieved higher accuracy in the prediction of LNI, compared to other nomograms, in several external validation cohorts, being the most applied in Europe (9–12). Most of these tools were developed in the pre-multi parametric magnetic resonance imaging (mpMRI)—era, taking therefore into consideration only clinical and systematic biopsy information. In this context, the novel Briganti 2019 nomogram has been developed in order to include the clinical staging at mpMRI and the Gleason score (GS) at MRI-targeted biopsy, with the aim of exploiting the ability of this diagnostic technique to detect clinically significant (cs) PCa, and thus, better identifying those patients with a greater risk of LNI. Several external validation studies had investigated the accuracy of the Briganti 2019 nomogram, with an AUC ranging between 76 and 80% using a risk threshold of 7% (13–16). However, few studies have directly compared the accuracy of Briganti 2012 and 2019 nomograms, and therefore, the potential added value of mpMRI in nodal staging. Moreover, there is a lack in the literature about the performance of these models in patients with intermediate risk (IR) disease, which is the most heterogeneous category of PCa patients. In this sub-cohort, the indication for ePLND remains indeed greatly controversial. The present study aimed to externally validate and compare the accuracy of Briganti 2012 and 2019 nomograms in a cohort of patients treated with robot-assisted radical prostatectomy (RARP) and anatomically defined ePLND in a tertiary referral hospital.

MATERIALS AND METHODS

Study Design and Data Collection

After institutional review board approval, we retrospectively collected perioperative data of 1,638 consecutive patients treated with RARP and ePLND for clinically localized PCa, between December 2014 and August 2021. Preoperative data included total prostate-specific antigen (PSA) level (ng/ml), clinical T stage (cT stage) based on digital rectal examination (DRE), and the number of positive and total cores, as well as the GS at systematic prostate biopsy. The cT stage was determined according to the cTNM classification 2010. Prostate biopsies were performed according to the EAU guidelines recommended regimen of 12 systematic biopsies. For those patients who underwent mpMRI, we considered the prostate imaging-reported and data system (PI-RADS) score of the main suspected lesion, the maximal target lesion diameter, the presence of extra-capsular extension (ECE) or seminal vesicles invasion (SVI). We included patients with at least one PI-RADS score ≥3 lesion receiving at least two MRI-targeted biopsies for each detected lesion plus at least 10 random biopsies. The primary and secondary GS as well the Gleason group (GG) of biopsy specimens were evaluated according to the ISUP 2014 grading system. All patients were treated with RARP (DaVinci system Xi, Intuitive Surgical, CA, USA) performed by three expert urologic surgeons. No patients received neoadjuvant therapy before surgery. The ePLND template applied involved the removal of nodes overlying the external iliac vessels and internal iliac artery, as well as nodes located within the obturator fossa. Postoperative data included final GG, pathological staging, the total number of resected lymph node, and the number of positive nodes. The preoperative risk of LNI was calculated for all patients using Briganti 2012 nomogram, merging systematic and targeted biopsies for patients who underwent mpMRI and targeted biopsy. The Briganti 2019 nomogram was used only in patients who had performed mpMRI with the combination of targeted and random biopsy. Intermediate Risk (IR) PCa was defined according with D’Amico
classification (i.e., PSA 10–20 ng/ml or GS = 7 or cTstage = cT2b).

**Study Outcomes**
The primary outcome of the study is to evaluate separately the accuracy and clinical usefulness of both Briganti 2012 and 2019 nomograms. Subsequently, we directly compare the two models in a sub-cohort of patients with mpMRI, mpMRI targeted biopsy, and systematic biopsy. The secondary outcome is to assess and compare the performance of both nomograms in a sub-cohort of patients affected by IR PCa.

**Statistical Analysis**
Continuous variables were reported as median and IQR and compared with the Mann-Whitney test. Categorical variables were reported as proportions and compared with the Pearson chi-squared test or Fisher’s exact test, as appropriate. External validation of the models followed the TRIPOD recommendations (17). Previously published regression coefficients were used to calculate the individual risk of LNI (14, 18). The performances of Briganti 2012 and 2019 nomograms were evaluated in terms of discrimination, calibration, and clinical usefulness. The accuracy was evaluated using the area under the curve (AUC) of the receiver operating characteristics (ROC) curve. The calibration plot was used to evaluate the concordance between the predicted frequencies (x-axis) and the observed frequencies (y-axis), assessing in this way the extent of over-and under-estimation of the models. Decision curve analysis (DCA) was used to evaluate the net benefit of the models according to the established cut-off. The same analyses were performed for the entire population and separately for the subgroup of IR PCa. A two-sided p-value < 0.05 was taken to indicate statistical significance. Statistical analyses were performed with STATA/SE 17 (StataCorp, College Station, TX, USA).

**RESULTS**
Overall, 752 patients presented the available necessary data to calculate the Briganti 2012 nomogram; while the 2019 model was applied in 327 (43.5%) patients with available mpMRI, targeted, and systematic biopsies information. Baseline characteristics of the main patient cohort are presented in **Table 1**. Overall, 78 patients (10.4%) had LNI on final pathological examination, with a median (IQR) of 13 (9–18) resected nodes. Significant differences were observed between pN0 and pN1 patients in most of the considered characteristics.

The AUCs of Briganti 2012 and 2019 nomograms were 0.84 and 0.82, respectively. When directly comparing these models in the sub-cohort of 327 patients with MRI data, the AUCs were respectively 0.85 and 0.82, and this difference was not statistically significant (p = 0.296) (**Figure 1**). Graphical representation of calibration plots of both models showed a satisfactory concordance between predicted probabilities and observed frequencies of LNI, with a general slight tendency to underestimation (**Figure 2**). The DCAs of the two models were similar, with a slightly higher net benefit for Briganti 2012 nomogram in the ability to identify true positive patients and
reduce the number of unnecessary PLND, considering threshold probabilities below 20% (Figure 3).

Table 2 shows the proportion of missing LNI according to the guidelines suggested cut-off of 5% and 7% for Briganti 2012 and 2019, respectively. Briganti 2012 allowed to avoid 56.2% of ePLNDs missing 2.4% of patients with LNI, while using Briganti 2019 nomogram would result in 54.1% of ePLNDs avoided and 5.1% missed patients with LNI.

Among the entire population, 518 (68.9%) patients harbored intermediate-risk PCA according to D’Amico criteria. In this sub-cohort, the Briganti 2012 AUC was 0.82, while in the 237 (45.7%) intermediate-risk patients with positive mpMRI, positive targeted, and systematic biopsies the Briganti 2019 AUC was 0.77. Comparing the accuracy of the two models in these 237 patients the AUCs were 0.85 and 0.77, respectively for the 2012 and 2019 Briganti nomogram, and this difference was statistically significant ($p = 0.0413$). Calibration plots were similar for both the models, while the DCA showed a better net benefit for the Briganti 2012 compared to Briganti 2019 nomogram. Finally, considering a cut-off of 5% for Briganti 2012, 269 out of 518 (51.9%) ePLNDs might have been avoided among IR PCA patients, missing 8 (3%) LNI; using a cut-off of 7% for Briganti 2019, 114 out of 237 (48.1%) IR patients would have been spared from a useless ePLNDs, missing 5 (2.4%) cases of LNI.

**DISCUSSION**

The importance of performing an accurate nodal staging in patients with PCa is essential for treatment planning and subsequent follow-up. According to current guidelines, the decision to perform nodal dissection should be guided by the pre-operative probability of LNI. The purpose of the current study is to externally validate and directly compare the performance of the Briganti 2012 nomogram, which is the most applied model in Europe, and the recently introduced Briganti 2019, which in addition to the first one, includes mpMRI and mpMRI-targeted biopsy data. Our results showed a similar accuracy to discern between patients with and without LNI, with non-statistically different AUCs for Briganti 2012 and 2019. Similar results were observed for calibration analysis and clinical net-benefit at DCAs, with a slight advantage of Briganti 2012 over the 2019 model. These results were in line with those observed in previous external validation studies. Oderda et al. performed a multi-institutional external validation of several nomograms for the prediction of LNI, including both Briganti 2012 and 2019 nomograms. The results of the direct comparison in 444 patients,
showed how the 2012 model outperformed the 2019 nomogram in terms of accuracy (AUC: 0.79 vs. 0.76, respectively) and net-benefit, although without a statistically significant difference (16). Diamond et al. found the same AUC of 0.8 for both Briganti 2012 and 2019, but with a better net benefit for the 2019 model (15). On the other hand, Gandaglia et al. in a multi-institutional validation cohort comparing the performance of Briganti 2019 nomogram with those of Briganti 2012, 2017 and Memorial Sloan Kettering Cancer Center models, found a higher AUC for Briganti 2019 (79 vs. 75 vs. 65 vs. 74%), a better calibration and the highest net-benefit (13). These findings show how the role of mpMRI and mpMRI-targeted biopsy in PCa staging is still debated and not well-defined, especially with regards to nodal staging. It is well-established that the sensitivity and specificity of mpMRI in the direct detection of metastatic nodes, based on morphological characteristics, are not sufficient (19, 20); however, several studies have found that the presence of ECE and SVI at mpMRI are independent predictors of adverse pathological features such as Extra-Prostatic Disease (EPE), GG upgrading and LNI (21–23). Multiparametric-MRI has been shown to have higher accuracy than clinical and biopsy quantitative histology features in predicting EPE (24–27). Despite this, mpMRI remains characterized by a suboptimal capability to identify the presence of ECE and SVI with high specificity but a poor sensitivity, as shown by the statistically significant difference between clinical MRI stage and pathological stage at RP (p < 0.0001) observed in our study (24, 28–30). Actually, mpMRI is not considered a reliable tool for local staging of PCa, and its suboptimal rate of ECE and SVI detection could negatively affect the ability of the 2019 nomogram to predict LNI. This lack of performance improvement could also be explained by other clinical and technical characteristics. First, the high variability of mpMRI interpretation among different readers and a lack of standardization of EPE criteria could impact the reproducibility and the accuracy of the technique (31). Second, MRI-targeted biopsy is a highly operator-dependent procedure, with wide variability in terms of results according to operator experience (32). Finally, in our study, we included mpMRI conducted with both 1.5T and 3T magnetic fields, where 1.5T procedures were certainly less precise in identifying extra-prostatic diseases (33).

We also analyzed the performance of both Briganti 2012 and 2019 nomograms in a sub-cohort of 518 IR PCa patients. Intermediate risk represents the most frequent but also the most heterogeneous PCa category, with a reported rate of LNI ranging from 3.7% to 20.1% (34). In this population, the role of ePLND is often debated and therefore the nomograms play a major role in deciding whether to perform ePLND. In contrast with the results in the general population, in the IR group, the Briganti 2012 nomogram significantly outperformed the Briganti 2019 in terms of accuracy (0.85 vs. 0.77). Moreover, the older nomogram presented a better calibration and a higher net benefit compared to the newer one. As previously discussed, also in the IR PCa patients we found fewer cases of ECE and SVI identified on mpMRI compared to those found on final pathological examination, which might affect the ability of the 2019 model to identify the LNI.

Overall, our work showed that, in a real-life setting, mpMRI and MRI-targeted biopsy provide a limited additional value in improving the accuracy of clinical predictors of LNI. In this context, possible future developments could come from the widespread adoption of PSMA PET/CT. The diagnostic accuracy of PSMA PET/CT was found to be significantly higher than that of conventional imaging techniques in the detection of nodal metastasis in intermediate-high risk PCa, although not such as to replace ePLND (35–37). On the contrary, its role in the local staging remains controversial with several limitations and has not been shown to be superior to mpMRI (38–40). The first study that incorporated the PSMA PET/CT findings in the commonly used nomograms for the prediction of LNI showed an improvement in all models’ performance (41). Therefore, it is likely that in the future ePLND will be guided by nomograms integrating both mpMRI and PSMA PET/CT data.

![FIGURE 3](image-url) | Decision curve analysis of Briganti 2012 and 2019 nomograms.

---

**TABLE 2 | Results of Briganti 2012 and 2019 application.**

|                  | Total population |                  |                  |                  |
|------------------|------------------|------------------|------------------|------------------|
|                  | Briganti 2012 < 5% | Briganti 2012 ≥ 5% | Total            |                  |
| pN0              | 413 (97.6%)       | 261 (79.3%)      | 674 (89.6%)      |                  |
| pN1              | 10 (2.4%)         | 88 (20.7%)       | 78 (10.4%)       |                  |
| Total            | 423 (56.2%)       | 329 (43.8%)      | 752 (100%)       |                  |

|                  | (B) mpMRI population |                  |                  |                  |
|------------------|----------------------|------------------|------------------|------------------|
|                  | Briganti 2012 < 5%   | Briganti 2012 ≥ 5% | Total            |                  |
| pN0              | 153 (97.4%)          | 132 (40.5%)      | 285 (87.1%)      |                  |
| pN1              | 4 (2.6%)             | 38 (11.7%)       | 42 (12.8%)       |                  |
| Total            | 157 (48%)            | 170 (52%)        | 327 (100%)       |                  |

|                  | Briganti 2019 < 7%   | Briganti 2019 ≥ 7% | Total            |                  |
| pN0              | 168 (94.9%)          | 112 (74.7%)       | 280 (85.6%)      |                  |
| pN1              | 9 (5.1%)             | 38 (10.7%)        | 47 (14.4%)       |                  |
| Total            | 177 (54.1%)          | 150 (45.9%)       | 327 (100%)       |                  |

(A) refers to the total population (752 patients); (B) refers to the mpMRI population (327 patients).
REFERENCES

1. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. (2008) 54:544–52. doi: 10.1016/j.eururo.2008.05.023
2. Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. (2014) 65:20–5. doi: 10.1016/j.eururo.2013.03.053
3. Mottet N, Bastian P, Bellmunt J, Van den Bergh RCN, Bolla M, Van Casteren NJ, et al. EAU - EANM - ESTRO - ESUR - SIOG: guidelines on prostate cancer. Eur Assoc Urol. (2020) 79:243–62. doi: 10.1016/j.eururo.2020.09.042
4. Abdollah F, Suardi N, Gallina A, Bianchi M, Tutilo M, Passoni N, et al. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol. (2013) 24:1459–66. doi: 10.1093/annonc/mdt120
5. Fossati N, Willenme PPM, van den Broeck T, Van den Bergh RCN, Yuan CY, Briere E, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol. (2017) 72:84–109. doi: 10.1016/j.eururo.2016.12.003
6. Ploussard G, Briganti A, de La Taille A, Haeae A, Heidenreich A, Menon M, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications - A systematic review of the literature. Eur Urol. (2014) 65:7–16. doi: 10.1016/j.eururo.2013.03.057
7. Withrow DR, Drgot JM, Siemens DR, Groome PA. Therapeutic value of lymph node dissection at radical prostatectomy: a population-based case-cohort study. BJU Int. (2011) 108:209–16. doi: 10.1111/j.1464-410X.2010.09805.x
8. Preissler F, van den Bergh RCN, Gandaglia G, Ost P, Surcel IC, Sooriakumaran P, et al. Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with D’Amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study. J Urol. (2020) 203:338–43. doi: 10.1097/JU.0000000000001054
9. Walz J, Blado F, Rousseau B, Laroche J, Salem N, Gravis G, et al. Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. Urology. (2012) 79:546–51. doi: 10.1016/j.urology.2011.11.036
10. Bandini M, Marchioni M, Pompe RS, Tian Z, Gandaglia G, Fossati N, et al. First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU Int. (2018) 121:592–9. doi: 10.1111/bju.14074
11. Pelleron N, Seigneurin A, Heraud C, Verry C, Bolla M, Rambeaux JJ, et al. External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients. World J Urol. (2021) 39:1489–97. doi: 10.1007/s00345-020-03322-9
12. Hueting TA, Cornel EB, Somford DM, Jansen H, Van Basten JPA, Pleijhuis RG, et al. External validation of models predicting the probability of lymph node involvement in prostate cancer patients. Eur Urol Oncol. (2018) 1:411–7. doi: 10.1016/j.euo.2018.04.016
13. Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, et al. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection. Eur Urol. (2020) 78:138–42. doi: 10.1016/j.eururo.2020.03.023
14. Gandaglia G, Ploussard G, Valero M, Matti A, Fiori C, Fossati N, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. Eur Urol. (2019) 75:506–14. doi: 10.1016/j.eururo.2018.10.012
15. Diamand R, Oderda M, Albisinni S, Fourcade A, Fournier G, Benamran D, et al. External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study. Urol Oncol Semin Original Investig. (2020) 38:847.e9–16. doi: 10.1016/j.urolonc.2020.04.011
16. Oderda M, Diamand R, Albisinni S, Calligaris G, Carbone A, Falcone M, et al. Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. BJU Int. (2021) 127:318–25. doi: 10.1111/bju.15220
17. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD Statement. *Eur Urol*. (2015) 67:1142–51. doi: 10.1016/j.eururo.2014.11.025

18. Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. *Eur Urol*. (2012) 61:480–7. doi: 10.1016/j.eururo.2011.10.044

19. Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. *Eur Urol*. (2011) 60:125–30. doi: 10.1016/j.eururo.2011.01.015

20. Muteganya R, Goldman S, Aoun F, Roumeguère T, Albisinni S. Current imaging techniques for lymph node staging in prostate cancer: a review. *Front Surg*. (2018) 5:74. doi: 10.3389/fsurg.2018.00074

21. Brembilla G, Dell’Oglio P, Stabile A, Ambrosi A, Cristel G, Brunetti L, et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. *Eur Radiol*. (2018) 28:1969–76. doi: 10.1007/s00330-017-5229-6

22. Rayn KN, Bloom JB, Gold SA, Hale GR, Baicocco JA, Mehralivand S, et al. Added value of multiparametric magnetic resonance imaging to clinical nomograms for predicting adverse pathology in prostate cancer. *J Urol*. (2018) 200:1041–7. doi: 10.1016/j.juro.2018.05.094

23. Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumiguié M, et al. The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging–targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. *Eur Urol*. (2020) 77:733–41. doi: 10.1016/j.eururo.2019.09.005

24. de Rooij M, Hamoen EJH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. *Eur Urol*. (2016) 70:233–45. doi: 10.1016/j.eururo.2015.07.029

25. Boesen L, Chabanova E, Legager V, Baldev I, Mikines K, Thomsen HS. Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. *Eur Radiol*. (2015) 25:1776–85. doi: 10.1007/s00330-014-3543-9

26. Feng TS, Sharif-Afshar AR, Wu J, Li Q, Luthringer D, Saouaf R, et al. Multiparametric MRI improves accuracy of clinical nomograms for predicting extracapsular extension of prostate cancer. *Urology*. (2015) 86:332–7. doi: 10.1016/j.urology.2015.06.003

27. Gupta RT, Faridi KE, Singh AA, Passoni MN, Garcia-Reyes K, Madden JF, et al. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. *Urol Oncol*. (2014) 32:1292–9. doi: 10.1016/j.suronc.2014.04.017

28. Caglic I, Kovac V, Barrett T. Multiparametric MRI - Local staging of cancer and beyond. *Radiol Oncol*. (2019) 53:159–70. doi: 10.2478/raon-2019-0021

29. Billing A, Buchner A, Stief C, Roosen A. Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. *World J Urol*. (2015) 33:923–8. doi: 10.1007/s00345-014-1448-5

30. Lee H, Kim CK, Park BK, Sung HH, Han DH, Jeon HG, et al. Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy. *World J Urol*. (2017) 35:929–34. doi: 10.1007/j.juro.2017.02.2766

31. Stabile A, Giganti F, Kasivisvanathan V, Giannarini G, Moore CM, Padhani AR, et al. Factors influencing variability in the performance of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer: a systematic literature review. *Eur Urol Oncol*. (2020) 3:145–67. doi: 10.1016/j.euo.2020.02.005

32. Checchiucci E, Piramide F, Ampareore D, De Cillis S, Granato S, Sica M, et al. Beyond the learning curve of prostate MRI/TRUS target fusion biopsy after more than 1000 procedures. *Urology*. (2021) 155:39–45. doi: 10.1016/j.urology.2021.06.021

33. Ulrich T, Quentin M, Oelers C, Dietzel F, Sawicki LM, Arsov C, et al. Magnetic resonance imaging of the prostate at 15 versus 30 T: a prospective comparison study of image quality. *Eur J Radiol*. (2017) 90:192–7. doi: 10.1016/j.ejrad.2017.02.044

34. Briganti A, Capitanio U, Abdollah F, Gallina A, Suardi N, Bianchi M, et al. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. *Prostate*. (2012) 72:499–506. doi: 10.1002/pros.21451

35. Hofman MS, Lawrencehuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet*. (2020) 395:1208–16. doi: 10.1016/S0140-6736(20)30314-7

36. Maurer T, Eiber M, Schwarzer M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. *Nat Rev Urol*. (2016) 13:226–35. doi: 10.1038/nruro.2016.26

37. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawnh-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. *JAMA Oncol*. (2021) 7:1635–42. doi: 10.1001/jamaoncol.2021.3771

38. Sonni I, Felker E, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, et al. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostastic localization, and local extension of primary prostate cancer: a single-center imaging study with histopathology gold-standard. *J Clin Oncol*. (2021) 39(6_suppl):193. doi: 10.1200/JCO.2021.39.6_suppl.193

39. Muehlematter UJ, Burger IA, Becker AS, Schwakart K, Hotker AM, Reiner CS, et al. Diagnostic accuracy of multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. *Radiology*. (2019) 293:350–8. doi: 10.1148/radiol.2019190687

40. Arslan A, Karaarslan E, Güner AL, Saglican Y, Tuna MR, Kural AR. Comparing the diagnostic performance of multiparametric prostate MRI versus 68Ga-PSMA PET-CT in the evaluation lymph node involvement and extraprostatic extension. *Acad Radiol*. (2020). doi: 10.1016/j.acra.2020.07.011

41. Meijer D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, Morton A, Axley JW, et al. External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study. *Eur Urol*. (2021) 80:234–42. doi: 10.1016/j.eururo.2021.05.006

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Frego, Paciotti, Buffi, Magfeli, Contieri, Avolio, Fasulo, Uleri, Lazzeri, Hurler, Saita, Guazzoni, Casale and Lughazzani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*